This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LEON GOLDMAN, M.D.

AMA Arch Derm. 1960;81(6):971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

At the VII International Congress of Leprology in Tokyo, Mayer and Davey¹ reported on the diphenyl thiourea compounds in regard to their antituberculosis and antileprosy activity. This compound, known as SU 1906, or DPT, is a substituted thiocarbanilide, 4-butoxy-4'di-methyl-amino-diphenyl thiourea, which has been studied now for over four years in the treatment of leprosy. The most extensive work was done by Davey² of the Uzuakoli Research Centre in Nigeria, West Africa. One of the important properties of this material was its freedom from toxicity.

Because of the interest of the dermatologist in drugs used in the treatment of Hansen's disease, it was decided to use this nontoxic compound in the study of various dermatoses. Because of the presence of a thio compound, rosacea was the first dermatosis selected. It is admittedly difficult to assay the value of any oral therapy in rosacea, so 56 patients with severe rosacea . . . [Full Text PDF of this Article]

Author Affiliations
Cincinnati

From The Department of Dermatology of the College of Medicine of the University of Cincinnati.

Footnotes
Submitted for publication Sept. 11, 1959.

Diphenyl thiourea, SU 1906, obtained from Dr. H. J. Bornhold, Research Department, Division of Clinical Investigation, Ciba Pharmaceutical Products Inc., Summit, N.J.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?